Supplementary file 1_Medicinal plants and compounds for chronic bronchitis treatment: efficacy and action mechanisms.docx

BackgroundChronic bronchitis (CB) is a common yet heterogeneous condition characterized by persistent inflammation, oxidative stress, airway hyperresponsiveness, and mucus hypersecretion. As an early stage of various severe pulmonary diseases, current therapeutic strategies remain unsatisfactory. Substantial evidence indicates that medicinal plants and compounds hold potential for treating inflammatory lung disorders. This study aims to consolidate recent and reliable evidence concerning the multi-targeted roles and underlying molecular mechanisms of these natural products in the treatment of CB.
MethodsThis systematic review followed a prospectively registered protocol (PROSPERO ID: CRD42024588912). A comprehensive literature search encompassed multiple electronic databases, including PubMed, Scopus, Embase, Web of Science, VIP, Wan-fang, SinoMed, and the China National Knowledge Infrastructure Study selection strictly adhered to the PICOS principles to systematically identify medicinal plants and compounds with therapeutic potential against Chronic bronchitis.
ResultsThe results identified 13 medicinal plants and 19 compounds that exhibited anti-inflammatory activity. Additionally, 8 plants and 12 compounds demonstrated further therapeutic effects, including antioxidant, anti-mucus, and potential bronchodilatory activities. The underlying mechanisms primarily involved the NF-κB, PI3K/AKT/mTOR, TLR4, MAPK, and Nrf2 pathways. Ursolic acid emerged as the most promising clinical candidate.
ConclusionThis review represents the first comprehensive synthesis of experimentally verified efficacy and mechanisms associated with medicinal plants and compounds in CB treatment. Preclinical animal studies have confirmed the therapeutic benefits of these natural agents in alleviating CB symptoms, establishing a solid foundation for novel drug development and underscoring their considerable translational potential.

背景：慢性支气管炎（Chronic Bronchitis, CB）是一种常见且具有异质性的疾病，以持续炎症、氧化应激、气道高反应性及黏液高分泌为核心特征。作为多种重症肺部疾病的早期阶段，当前的临床治疗策略仍不尽如人意。大量研究证据表明，药用植物及其活性成分在治疗炎症性肺部疾病方面具备潜在应用价值。本研究旨在整合近年来的可靠研究证据，阐明此类天然产物在慢性支气管炎治疗中的多靶点作用及其潜在分子机制。
方法：本系统评价遵循预先注册的研究方案（PROSPERO注册号：CRD42024588912）。研究人员通过PubMed、Scopus、Embase、Web of Science、维普数据库（VIP）、万方数据库、中国生物医学文献数据库（SinoMed）及中国知网（China National Knowledge Infrastructure）等多个电子数据库开展全面的文献检索。研究筛选严格遵循PICOS原则，以系统识别具有抗慢性支气管炎治疗潜力的药用植物及其活性成分。
结果：本研究共筛选出13种具有抗炎活性的药用植物及19种活性成分。此外，另有8种植物及12种成分展现出额外的治疗功效，涵盖抗氧化、抗黏液分泌及潜在的支气管扩张活性。其潜在分子机制主要涉及NF-κB、PI3K/AKT/mTOR、TLR4、MAPK及Nrf2信号通路。其中，熊果酸（Ursolic acid）被认定为最具开发前景的临床候选药物。
结论：本综述首次全面整合了经实验验证的、用于慢性支气管炎治疗的药用植物及其活性成分的疗效与相关分子机制。临床前动物实验已证实，此类天然制剂在缓解慢性支气管炎症状方面具有明确的治疗价值，为新型药物研发奠定了坚实基础，同时凸显了其可观的转化应用潜力。